Details werden geladen...
New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight management experience for people l...
Press release - No. 13 / 2026
Ähnliche Seiten
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association ("ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Stud...
https://www.manilatimes.net/2026/06/06/tmt-newswire/globenewswire/biomea-fusion-presents-new-clinical-and-translational-data-for-icovamenib-at-the-american-diabetes-association-ada-86th-scientific-sessions-and-announces-expansion-of-ongoing-phase-i-bmf-650-study/2359908Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific...
https://www.manilatimes.net/2026/06/05/tmt-newswire/globenewswire/eledon-announces-presentation-of-updated-data-from-investigator-initiated-islet-transplant-trial-of-tegoprubart-in-patients-with-type-1-diabetes-at-american-diabetes-association-ada-2026-scientific-sessions/2359225
Verdiva Bio Limited: Verdiva Bio Presents Preclinical Data on Investigational Obesity Drug Candidates at the American Diabetes Association 86th Scientific Sessions
https://www.finanznachrichten.de/nachrichten-2026-06/68696937-verdiva-bio-limited-verdiva-bio-presents-preclinical-data-on-investigational-obesity-drug-candidates-at-the-american-diabetes-association-86th-scient-004.htmAntag Therapeutics presents positive Phase 1 results at the 2026 Scientific Sessions of the American Diabetes Association for AT7687, a first-in-class GIPR antagonist | The Manila Times
https://www.manilatimes.net/2026/06/08/tmt-newswire/globenewswire/antag-therapeutics-presents-positive-phase-1-results-at-the-2026-scientific-sessions-of-the-american-diabetes-association-for-at7687-a-first-in-class-gipr-antagonist/2360284Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 a...
https://www.manilatimes.net/2026/06/08/tmt-newswire/pr-newswire/ascletis-reinforces-its-differentiated-obesity-portfolio-at-american-diabetes-association-ada-2026-scientific-sessions-showcasing-asc30-clinical-data-and-exciting-preclinical-findings-from-asc37-and-asc39/2360317